Abstract
The purpose of the study was to identify factors that could predict good yields of peripheral blood stem cells (PBSC) in multiple myeloma (MM). Fifty-one MM patients, nine with refractory disease and 42 in plateau phase, were mobilized with high-dose cyclophosphamide (HD-Cy) at 4 g/m2 followed by granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/day. Clinical and laboratory parameters at the time of mobilization were analyzed for correlations with the number of CD34+ cells collected, with the colony-forming unit granulocyte–macrophage (cfu-gm) count, and the mononuclear cell (mnc) count. in univariate analysis, low wbc count, low platelet count, prior exposure to melphalan, and an interval >6 months from the start of treatment correlated with poor yields of CD34+ cells. low platelet count, prior exposure to melphalan or to radiotherapy, and an interval >6 months from the start of treatment were associated with a low cfu-gm count. on the basis of these data, we defined a scoring system able to predict the yield of the mobilizing procedure. according to this system, the presence of more than one risk factor (low wbc and platelet counts, prior exposure to melphalan, interval from first chemotherapy >6 months) was predictive of insufficient collections when a conventional combination of mobilizing measures are used. Bone Marrow Transplantation (2000) 26, 283–286.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Attal M, Harousseau J-L, Stoppa AM et al. Prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97
Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793
To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenic bone marrow transplants Bone Marrow Transplant 1992 9: 277–284
Gianni AM, Siena S, Bregni M et al. Granulocyte–macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation Lancet 1989 2: 580–585
Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma Bone Marrow Transplant 1996 17: 691–697
Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cells collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors Bone Marrow Transplant 1992 9: 11–17
To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of haemopoietic stem cells from the peripheral blood Exp Hematol 1990 18: 442–447
Desikan KR, Barbogie B, Jagannath S et al. Comparable engraftment kinetics following peripheral blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma J Clin Oncol 1998 16: 1547–1553
Kobbe G, Sohngen D, Bauser U et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma Ann Hematol 1999 78: 456–462
Russell NH, McQuaker G, Stainer C et al. Stem cell mobilization in lymphoproliferative diseases Bone Marrow Transplant 1998 22: 935–940
Sautois B, Fraipont V, Baudoux E et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields Haematologica 1999 84: 342–349
Besinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells J Clin Oncol 1995 13: 2547–2555
Scheid C, Draube A, Reiser M et al. Using at least 5 × 106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation Bone Marrow Transplant 1999 23: 1177–1181
Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplant for multiple myeloma. identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596
Gandhi MK, Jestice K, Scott MA et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients Bone Marrow Transplant 1999 23: 9–13
Demirer T, Buknener CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma Bone Marrow Transplant 1996 17: 937–941
Drake M, Ranaghan L, Morris TCM et al. Analysis of the effects of prior therapy on progenitor cell yield: use of a chemotherapy score system Br J Haematol 1997 98: 745–749
Haas R, Möhle R, Frühauf S et al. Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitors cells in malignant lymphoma Blood 1994 83: 3787–3794
Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitors cells in 200 patients with lymphoid malignancies Br J Haematol 1998 103: 235–242
Krieger MS, Schiller G, Berenson JR et al. Collection of peripheral blood progenitors cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cells Bone Marrow Transplant 1996 18: 1–7
Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitors cell collection in multiple myeloma: predictors and management of inadequate collections Br J Haematol 1996 93: 142–145
Facon T, Harousseau JL, Maloisel F et al. Stem cell factor in combination with filgastrim after chemotherapy improves peripheral blood progenitors cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial Blood 1999 94: 1218–1225
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corso, A., Caberlon, S., Pagnucco, G. et al. Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant 26, 283–286 (2000). https://doi.org/10.1038/sj.bmt.1702514
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702514
Keywords
This article is cited by
-
Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma
Annals of Hematology (2020)
-
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT
Bone Marrow Transplantation (2013)
-
Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2
International Journal of Hematology (2009)
-
Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis
Annals of Hematology (2006)
-
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
Bone Marrow Transplantation (2001)